A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .
Cervical Cancer|Genital Wart|CIN1|CIN2|CIN3|Vain I|Vain III|Vin I|Vin II|Vin III|AIS|VAIN - Vaginal Intraepithelial Neoplasia 2
BIOLOGICAL: Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha)|BIOLOGICAL: Placebo
The person-year incidence of HPV 16 and 18-related CIN 2+ observed in Chinese women aged 18-45 years after receiving 3 doses of quadrivalent HPV vaccine at least 30 days ago., Over 30 months
The person-year incidence of HPV 6-, 11-, 16-, and 18-related 6-month Persistent Infection at least 30 days post Dose 3, from Month 7 up to Month 60|The person-year incidence of HPV 6-, 11-, 16-, and 18-related 12-month Persistent Infection at least 30 days post Dose 3, from Month 7 up to Month 60|The person-year incidence of HPV 6-, 11-, 16-, and 18-related disease (e.g., VIN1+ orAIN1+ or VAIN1+ and genital warts), from Month 7 up to Month 60|Percentage of Participants Who Report at any Injection-site and Systemic Adverse Event 30 minutes post any vaccination, 30 minutes after any dose of vaccination|Number of subjects with Adverse Events (AEs), Subjects with solicited and unsolicited AEs, From Day 0 to Month 30|Number of subjects with Severe adverse events (SAE), SAEs assessed include medical occurrences that results in death, are life threatening, require hospitalization or prolongation of hospitalization, results in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subjects., Through study completion，expected 60 months|Number of subjects with pregnancy events, Outcomes of pregnancies were Live infant NO apparent congenital anomaly (ACA) , Live infant, Elective termination NO ACA, Elective termination CA, Ectopic pregnancy, Spontaneous abortion NO ACA, Stillbirth, Lost to follow up and Pregnancy ongoing., Through study completion，expected 60 months|Number of subjects receiving the whole schedule vaccination with antibody responses as assessed by SCR, Month7|The neutralizing antibody level among the subjects receiving the whole schedule vaccination, Month7|The person-year incidence of non-vaccine-realted HPV types related CIN2+ observed in Chinese women aged 18-45 years at least 30 days post Dose 3, Through study completion，expected 60 months|The person-year incidence of non-vaccine-realted HPV types related disease (e.g., VIN1+ or AIN1+ or VAIN1+ and genital warts) observed in Chinese women aged 18-45 years at least 30 days post Dose 3, Through study completion，expected 60 months|The person-year incidence of HPV 6-, 11-, 16-, and 18-related 6-month and 12-month Persistent Infection at least 30 days post Dose 1, From Month 1 up to Month 60|The person-year incidence of HPV 16- and 18-related CIN2+ at least 30 days post Dose 1, From Month 1 up to Month 60|The person-year incidence of HPV 6-, 11-, 16- and 18-related diseases (e.g., VIN1+ or AIN1+ or VAIN1+ and genital warts) at least 30 days post Dose 1, From Month 1 up to Month 60
This study is designed to evaluate the vaccine efficacy, immunogenicity and safety of the 4-valent Human Papillomavirus (Types 6, 11, 16, and 18) Recombinant Vaccine (Hansenula Polymorpha) in Chinese Female Subjects Aged 18-45 Years .